Piper Sandler analyst David Amsellem upgraded Neurocrine Bio. (NASDAQ: NBIX) from Neutral to Overweight with a price target of $159.00 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE